Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
GANX Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Gain Therapeutics, Inc.NASDAQ: GANX
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow outflow grows to $0
Q1 FY2026 investing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month investing cash flow was $0.
Context
- Investing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 4.98M | -51.3% |
| FY2023 | 2023-12-31 | 10.22M | +169.2% |
| FY2022 | 2022-12-31 | (14.77M) | -15582.5% |
| FY2021 | 2021-12-31 | (94.21K) | — |
Investing Cash Flow vs competitors
How GANX compares with its peers on the latest reported figures
- GANX's LTM Mar 2026 investing cash flow of $0 is the smallest of the 9 companies compared; the peer median is $226.28K.
- Its year-over-year change of -100.0% is the lowest of 7, against a peer median of +112.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $95.77M | +227.3% | — | 1048.3% | |
| LTM Mar 2026 | $24.13M | +119.8% | — | — | |
| LTM Mar 2026 | $8.96M | +164.7% | — | 13.5% | |
| LTM Mar 2026 | $3.02M | — | +555.0% | 131.8% | |
| LTM Jun 2024 | $447.24K | — | — | 54.8% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $292.79K | +68.6% | — | — |
| LTM Mar 2026 | $186K | -83.7% | -83.5% | — | |
| LTM Apr 2026 | $5.32K | +105.8% | -59.4% | 0.3% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding GANX) | $226.28K | +112.8% | -59.4% | 54.8% | |
Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 839.37K | 1.53M | 3.26M | 2.39M | 1.8M |
| Change in Working Capital | (329.78K) | 1.51M | 442.23K | (1.08M) | (1.01M) |
| Accounts Receivables | (63.35K) | 3.63K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (521.39K) | 1.07M | (643.16K) | 274.89K | (468.61K) |
| Other Working Capital | 254.96K | 444.52K | 1.09M | (1.36M) | (537.91K) |
| Other Non-Cash Items | 999.87K | (206.86K) | (383.19K) | 143.52K | 804.94K |
| Operating Cash Flow | (12.37M) | (14.69M) | (18.87M) | (18.87M) | (18.47M) |
| Capital Expenditures | (94.21K) | (118.95K) | (15.36K) | (22.49K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (17.74M) | (1.96M) | 0 | 0 |
| Sales of Investments | 0 | 3.08M | 12.19M | 5M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (94.21K) | (14.77M) | 10.22M | 4.98M | 0 |
| Debt Repayment | (21.95K) | (78.77K) | (89.07K) | (90.88K) | (96.5K) |
| Common Stock Issued | 42.63M | 0 | 12.73M | 13.21M | 28.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (841.27K) | 0 | 0 | (109.36K) | 0 |
| Financing Cash Flow | 41.77M | (78.77K) | 12.64M | 13.01M | 28.45M |
| Effect of Forex Changes | 100.78K | (23.8K) | 488.4K | (527.17K) | 469.43K |
| Net Change in Cash | 29.41M | (29.57M) | 4.49M | (1.41M) | 10.46M |
| Free Cash Flow | (12.46M) | (14.81M) | (18.88M) | (18.9M) | (18.47M) |
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.